Neuronetics Schedules Q2 2026 Earnings Release and Conference Call
Event summary
- Neuronetics to release Q2 2026 financial and operating results on August 11, 2026.
- Conference call scheduled for 8:30 a.m. Eastern Time the same day.
- Company combines NeuroStar® TMS technology with Greenbrook's interventional psychiatry clinics.
- Offers both TMS and SPRAVATO® therapies through its clinic network.
The big picture
Neuronetics is positioning itself as a leader in interventional mental health by combining innovative treatment technologies with direct patient care. The company's integration of NeuroStar TMS technology with the Greenbrook network of clinics highlights its strategy to offer comprehensive, non-drug treatments for conditions like MDD and TRD. This approach aligns with broader industry trends towards personalized and non-invasive mental health solutions.
What we're watching
- Revenue Growth
- Whether Neuronetics can sustain its growth trajectory in the interventional mental health space.
- Market Expansion
- The pace at which the company expands its Greenbrook clinic network and integrates new therapies.
- Regulatory Compliance
- How changes in FDA regulations might impact the approval and use of NeuroStar and SPRAVATO® therapies.
Related topics